1 completed, 1 recruiting. 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Dulaglutide 0.75mg subcutaneous injection: new trials by email Literature Review of Dulaglutide 0.75mg subcutaneous injection trials Research Report on Dulaglutide 0.75mg subcutaneous injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician - Obese Diabetics, Obese Non Diabetic | Phase 3 | Completed | Zagazig University | 159 | 2025-10-18 | 2026-09-15 |
| GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery Dulaglutide 0.75mg subcutaneous injection - Myocardial Injury | Phase 4 | Recruiting | The University of Hong Kong | 372 | 2024-03-20 | 2026-05-04 |
Diabetes Mellitus, Type 2 (1) · Obesity (1)
The University of Hong Kong (1) · Zagazig University (1)
China (1) · Saudi Arabia (1)